What do systematic reviews say?

Low molecular weight heparin vs no prophylaxis

It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 0.14 [0.03, 0.61]
  2 studies · 369 participants
  Very low

Low molecular weight heparin vs no prophylaxis

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1978 participants
  GRADE not reported

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 1.85 [0.95, 3.59]
  5 studies · 1978 participants
  Moderate

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 0.98 [0.06, 15.72]
  1 study · 1451 participants
  Moderate

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 1.79 [0.84, 3.84]
  5 studies · 1978 participants
  Moderate

Low molecular weight heparin vs control

Does low molecular weight heparin prevent central venous… showed no clear difference in CVC‐related thrombosis ( compared with control (low certainty).

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  RR 0.68 [0.27, 1.75]
  2 studies · 787 participants
  Low

Low molecular weight heparin vs control

Does low molecular weight heparin prevent central venous… showed no clear difference in symptomatic CVC‐related thrombosis ( compared with control (low certainty).

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  RR 1.03 [0.21, 4.93]
  1 study · 158 participants
  Low

Low molecular weight heparin vs control

Does low molecular weight heparin prevent central venous… showed no clear difference in asymptomatic CVC‐related thrombosis ( compared with control (low certainty).

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  RR 1.17 [0.45, 3.08]
  1 study · 158 participants
  Low

Low molecular weight heparin vs control

Does low molecular weight heparin prevent central venous… showed no clear difference in major bleeding ( compared with control (low certainty).

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  RR 0.27 [0.05, 1.67]
  2 studies · 813 participants
  Low

Low molecular weight heparin vs control

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 813 participants
  Very low

Low molecular weight heparin vs control

• Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 813 participants
  Low

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.6 [0.42, 0.88]
  8 studies · 5324 participants
  Moderate

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.48 [0.35, 0.67]
  9 studies · 5408 participants
  High

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.57 [0.46, 0.71]
  10 studies · 5743 participants
  High

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.94 [0.83, 1.07]
  9 studies · 2681 participants
  Low

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 3.4 [1.2, 9.63]
  4 studies · 3105 participants
  Moderate

Low molecular weight heparin vs active control

Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 2.89 [0.12, 66.75]
  1 study · 51 participants
  Low
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.51 [0.22, 1.17]
  2 studies · 781 participants
  Moderate
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.14, 0.83]
  1 study · 439 participants
  High

Low molecular weight heparin vs active control

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.14 [0.01, 2.76]
  2 studies · 781 participants
  Low
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs active control

Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 2.89 [0.12, 66.75]
  Studies not reported
  GRADE not reported
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.13 [0.02, 1.03]
  2 studies · 781 participants
  Moderate
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.11 [0.01, 2.06]
  1 study · 439 participants
  Low

Low molecular weight heparin vs active control

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.81 [0.32, 2.04]
  2 studies · 781 participants
  Moderate
• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.17, 1.1]
  1 study · 439 participants
  Moderate